{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:48:06Z","timestamp":1778028486192,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00702-018-1897-x","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T11:25:45Z","timestamp":1530012345000},"page":"1351-1354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparing incobotulinumtoxinA (Xeomin\u00ae) and onabotulinumtoxinA (Botox\u00ae): identical potency labelling in the hemidiaphragm assay"],"prefix":"10.1007","volume":"125","author":[{"given":"Dirk","family":"Dressler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Bigalke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"1897_CR1","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","volume":"64","author":"R Benecke","year":"2005","unstructured":"Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949\u20131951","journal-title":"Neurology"},{"key":"1897_CR2","first-page":"493","volume":"86","author":"MF Brin","year":"1993","unstructured":"Brin MF, Blitzer A (1993) Botulinum toxin: dangerous terminology errors. J R Soc Med 86:493\u2013494","journal-title":"J R Soc Med"},{"key":"1897_CR3","first-page":"38","volume":"1","author":"E Buelbring","year":"1946","unstructured":"Buelbring E (1946) Observation on the isolated phrenic nerve diaphragm preparation in the rat. Br J Pharmacol 1:38\u201361","journal-title":"Br J Pharmacol"},{"issue":"Suppl 2","key":"1897_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1468-1331.2009.02877.x","volume":"16","author":"D Dressler","year":"2009","unstructured":"Dressler D (2009) Routine use of Xeomin\u00ae in patients pre-treated with Botox\u00ae. Eur J Neurol 16(Suppl 2):2\u20135","journal-title":"Eur J Neurol"},{"key":"1897_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00702-010-0372-0","volume":"117","author":"D Dressler","year":"2010","unstructured":"Dressler D (2010) Comparing Botox\u00ae and Xeomin\u00ae for the treatment of axillar hyperhidrosis. J Neural Transm 117:317\u2013319","journal-title":"J Neural Transm"},{"key":"1897_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1468-1331.2011.03559.x","volume":"19","author":"D Dressler","year":"2012","unstructured":"Dressler D (2012) Five-year experience with incobotulinumtoxinA (Xeomin\u00ae): the first botulinum toxin drug free of complexing proteins. Eur J Neurol 19:385\u2013389","journal-title":"Eur J Neurol"},{"key":"1897_CR7","first-page":"S23","volume":"123","author":"D Dressler","year":"2016","unstructured":"Dressler D, Bigalke H (2016) Comparing incobotulinumtoxina (Xeomin) and onabotulinumtoxina (Botox): identical potency labeling in the hemidiaphragm assay. Toxicon 123:S23","journal-title":"Toxicon"},{"key":"1897_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00702-011-0719-1","volume":"119","author":"D Dressler","year":"2012","unstructured":"Dressler D, Mander G, Fink K (2012) Measuring the potency labelling of onabotulinumtoxinA (Botox\u00ae) and Xeomin\u00ae in an LD50 assay. J Neural Transm 119:13\u201315","journal-title":"J Neural Transm"},{"key":"1897_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00702-013-1076-z","volume":"121","author":"D Dressler","year":"2014","unstructured":"Dressler D, Tacik P, Adib Saberi F (2014) Botulinum toxin therapy of cervical dystonia: comparing Botox\u00ae and Xeomin\u00ae. J Neural Transm 121:29\u201331","journal-title":"J Neural Transm"},{"key":"1897_CR10","unstructured":"European Pharmacopoeia 6.0 (2008a) Botulinum toxin type A for injection 1327\u20131329"},{"key":"1897_CR11","unstructured":"European Pharmacopoeia 6.0 (2008b) Statistical analysis of biological assays and tests. 5.3: 571\u2013600"},{"key":"1897_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1006\/exnr.1997.6580","volume":"147","author":"H Goeschel","year":"1997","unstructured":"Goeschel H, Wohlfahrt K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin: neutralizing and nonneutralizing antibodies\u2014therapeutic consequences. Exp Neurol 147:96\u2013102","journal-title":"Exp Neurol"},{"key":"1897_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/WNF.0b013e3181acefaf","volume":"32","author":"T Hunt","year":"2009","unstructured":"Hunt T, Clarke K (2009) Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A. Clin Neuropharmacol 32:28\u201331","journal-title":"Clin Neuropharmacol"},{"key":"1897_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/mds.22336","volume":"24","author":"G Kranz","year":"2009","unstructured":"Kranz G, Haubenberger D, Voller B, Posch M, Schnider P, Auff E, Sycha T (2009) Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study. Mov Disord 24:231\u2013236","journal-title":"Mov Disord"},{"key":"1897_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/jnnp.59.1.102","volume":"59","author":"MH Marion","year":"1995","unstructured":"Marion MH, Sheehy M, Sangla S, Soulayrol S (1995) Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiat 59:102\u2013103","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"1897_CR16","first-page":"494","volume":"86","author":"CD Marsden","year":"1993","unstructured":"Marsden CD (1993) Botulinum toxin: dangerous terminology errors. J R Soc Med 86:494","journal-title":"J R Soc Med"},{"key":"1897_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1006\/taap.1994.1181","volume":"128","author":"LB Pearce","year":"1994","unstructured":"Pearce LB, Borodic GE, First ER, MacCallum RD (1994) Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 128:69\u201377","journal-title":"Toxicol Appl Pharmacol"},{"key":"1897_CR18","first-page":"459","volume":"72","author":"D Ranoux","year":"2002","unstructured":"Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M (2002) Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72:459\u2013462","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1897_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","volume":"113","author":"P Roggenk\u00e4mper","year":"2006","unstructured":"Roggenk\u00e4mper P, Jost WH, Bihari K, Comes G, Grafe S, For the NT 201 Blepharospasm Study Team (2006) Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113:303\u2013312","journal-title":"J Neural Transm"},{"key":"1897_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/toxins8030065","volume":"8","author":"F Scaglione","year":"2016","unstructured":"Scaglione F (2016) Conversion ratio between Botox\u00ae, Dysport\u00ae, and Xeomin\u00ae in clinical practice. Toxins 8:65. \n                    https:\/\/doi.org\/10.3390\/toxins8030065","journal-title":"Toxins"},{"key":"1897_CR21","unstructured":"Van den Bergh P, Lison D, Dose standardisation of BTX (1996) 3rd International Dystonia Symposium, October 9\u201311, 1996, Miami, Florida. Affiliated National Dystonia Associations, Chicago, Illinois, p\u00a030"},{"key":"1897_CR22","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00415-009-5182-7","volume":"256","author":"K Wohlfarth","year":"2009","unstructured":"Wohlfarth K, Schwandt I, Wegner F, J\u00fcrgens T, Gelbrich G, Wagner A, Bogdahn U, Schulte-Mattler W (2009) Biological activity of two botulinum toxin type A complexes (Dysport\u00ae and Botox\u00ae) in volunteers. A double-blind, randomized, dose-ranging study. J Neurol 256:1201\u20131201","journal-title":"J Neurol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-018-1897-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-018-1897-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-018-1897-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T23:30:26Z","timestamp":1561505426000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-018-1897-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["1897"],"URL":"https:\/\/doi.org\/10.1007\/s00702-018-1897-x","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,26]]},"assertion":[{"value":"11 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DD received honoraria for consultations from Allergan, Ipsen, IAB-Interdisciplinary Working Group for Movement Disorders, Merz and Syntaxin. He is a shareholder of Allergan. He holds patents in botulinum toxin research. LP has nothing to disclose. HB is founder and co-owner of Toxogen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}